Rhinoconjunctivitis Clinical Trial
Official title:
A Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica
The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Parietaria judaica pollen extract in patients with rhinoconjunctivitis with or without associated mild asthma. In addition, surrogate efficacy parameters will be evaluated: immunoglobulin level changes and skin reactivity.
Parietaria judaica is a weed widespread throughout the Mediterranean área. Prevalence of
sensitization to Parietaria judaica's pollen is very high in the Mediterranean areas,
reaching 41.4% among allergic patients on the Spanish Mediterranean coast.
The study has been designed as an open trial which will be conducted in 4 Spanish sites.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
| Completed |
NCT02849210 -
A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea
|
Phase 1 | |
| Completed |
NCT02150343 -
Phase II HDM-SPIRE Safety and Efficacy Study
|
Phase 2 | |
| Completed |
NCT02340130 -
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
|
Phase 2 | |
| Completed |
NCT01949415 -
An Optional Investigation of Biomarkers of Efficacy
|
N/A | |
| Completed |
NCT01949441 -
ToleroMune House Dust Mite (HDM) Tolerability Study
|
Phase 2 | |
| Completed |
NCT01923792 -
ToleroMune House Dust Mite Follow on Study
|
N/A | |
| Completed |
NCT01949428 -
House Dust Mite Observational Study
|
N/A | |
| Completed |
NCT01447784 -
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
|
Phase 2 | |
| Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
| Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
| Completed |
NCT01720251 -
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
|
Phase 2 | |
| Completed |
NCT01620762 -
Phase III Cat-PAD Study
|
Phase 3 | |
| Completed |
NCT01448603 -
ToleroMune Ragweed Follow up Study
|
N/A | |
| Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
| Completed |
NCT00540631 -
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
|
Phase 3 | |
| Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
| Completed |
NCT00537342 -
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)
|
Phase 3 | |
| Completed |
NCT05540717 -
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
|
Phase 3 | |
| Completed |
NCT02844842 -
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
|